PDCD1 and neoplasm: In addition, eTregs express immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1), suggesting that controlling tumor-infiltrating Tregs may be a potential target for cancer immunotherapy [41–44].